Ketamine, an N-methyl-D-aspartate antagonist, presented one of the first major
breakthroughs in decades of antidepressant research. Ketamine's clinical effects take place …

Depression is the leading cause of global disability, disproportionately affecting females.
There is a pressing need for novel therapeutics as approximately 30% of those diagnosed …

Ketamine is a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that
produces rapid antidepressant action in some patients with treatment-resistant depression …

Over the past decade, ketamine, an NMDA receptor antagonist, has demonstrated fast-
acting antidepressant effects previously unseen with monoaminergic-based therapeutics …

Depression is the leading cause of disability worldwide, which necessitates novel
therapeutics and biomarkers to approach treatment of this neuropsychiatric disorder. To …

There is an urgent need for novel antidepressants, given that approximately 30% of those
diagnosed with depression do not respond adequately to first-line treatment. Additionally …

Major depressive disorder (MDD) is a devastating mental illness and the leading cause of
disability worldwide. Previous studies have suggested that synaptic plasticity in the …

The finding that reelin expression is significantly decreased in mood and psychotic
disorders, together with evidence that reelin can regulate key aspects of hippocampal …

Reelin is an extracellular matrix protein that regulates neural migration and dendritic
sprouting during brain development, and neural plasticity in the adult brain. Reelin is also …

Depression is an extremely common, devastating psychiatric syndrome with profound effects
on the structure of neurons and the proteins that they express. However, the …